


Devices and Data: Filling the Gap in the Essential 8

Joe Jensen, MD Grand Rounds 23 January 2023



GRAND ROUNDS





Disclosures


- Dose Health:
 - Co-founder, equity holder and current board member




GRAND ROUNDS



Δ





12.1.2. Strategies to Promote Lifestyle Modification

Recommendation for Strategies to Promote Lifestyle Modification

СО	R LOE	Recommendation
I	C- EO	Effective behavioral and motivational strategies to achieve a healthy lifestyle (ie, tobacco cessation, weight loss, moderation in alcohol intake, increased physical activity, reduced sodium intake, and consumption of a healthy diet) are recommended for adults with hypertension. S12.1.2-1,S12.1.2-2



GRAND ROUNDS



7




WE ARE NOT GOOD AT THIS NOR DO WE HAVE THE TIME




GRAND ROUNDS




ç












Life's Essential The Data • Meta-analysis of 48 studies with 2.6 Spline Model with 750 MET-minutes as reference level million patients 95% Confidence interval limits 1.40 1.30 -1.20 1.10 750 MET-min was baseline activity • Met-min of 1 = at rest € 0.90 • 6 mph = 10 METs -> 75 min/wk 0.80 • 4 mph = 5 METs -> 150 min/wk S 0.70 • 2 mph = 2.5 METs -> 300 min/wk 0.60 2000 3000 MET-minutes/week GRAND **ROUNDS**












Table 1: Sympathetic and Parasympathetic Effects on Target Organs Through Various Receptor Interactions

	Sympathetic			Parasympathetic
Organ	Receptor Subtype	Effect	Receptor Subtype	Effect
Heart	Beta-1, beta-2 ? also alpha and DA ₁	† Heart rate † Force of contraction † Conduction velocity † Automaticity (beta-2) † Excitability	M ₂	↓ Heart rate ↓ Force of contraction ↓ Conduction velocity
	Alpha-1	↑ Force of contraction		
Arteries	Beta-1 DA, beta-2	Coronary vasodilatation Vasodilatation (skeletal muscle) Vasoconstriction (coronary, pulmonary, renal and splanchnic circulations, skin and skeletal muscle) Splanchnic and renal vasodilatation	М	Vasodilatation in skin, skeletal muscle pulmonary and coronary circulations
Veins	Alpha-1, also alpha-2 Beta-2	Vasoconstriction Vasodilatation		
Lungs	Beta-2	Bronchodilation Inhibition of secretions	M ₁ , M ₃	Bronchoconstriction Stimulation of secretions
	Alpha-1	Bronchoconstriction		



GRAND ROUNDS



19

But Why? Heart Rate Variability (HRV)

- HRV: physiologic variation in the duration of intervals between sinus beats
- What about respiratory sinus arrhythmia?



GRAND ROUN<u>DS</u>



Respiratory Sinus Arrhythmia

Nemfqfyrts

- Diaphragm contracts
- Intrathoracic pressure lowers
- Atrial pressure lowers
- More blood returns to heart
- Atria expand
- Trigger baroreceptors
- Suppress vagal tone -> HR increase

J}mfqfyrts

- Diaphragm relaxes
- · Chest cavity decreases
- Intrathoracic pressure increases
- · Less venous return
- Inactivation of baroreceptors
- No longer suppress vagal tone
- HR decreases



GRAND ROUNDS



21

But Why? Heart Rate Variability (HRV)

- HRV: physiologic variation in the duration of intervals between sinus beats
- What about respiratory sinus arrhythmia?
 - HR increases with inspiration and decreases with expiration
- Root mean square of the differences in successive R-R intervals (RMSSD) is preferred
- Higher HRV = higher parasympathetic input



GRAND ROUNDS



But Why? Heart Rate Variability

Table 3: Mortality Risk Associated with Various Heart Rate Variability Measurements Using Ambulatory ECG

Study Name	Number of Patients	Monitoring Method	HRV parameters	Conclusions		
Tsuji et al. 1994 ^{si} (Framingham)	736	2-hour ambulatory ECG	VLFP, LFP, HFP, LFP/HFP, TP, SDNN, rMSSD, pNN50+	InLF <1 SD from mean had increased all-cause mortality (HR 1.70, 95 % CI [1.37–2.09])		
Tsuji et al. 1996 ¹¹ (Framingham Offspring)	2,501	2-hour ambulatory ECG	VLFP, LFP, HFP, LFP/HFP, TP, SDNN, rMSSD, pNN50+	All HRV parameters except LFP/HFP associated with increased risk of cardiac events (p=0.016-0.0496); adjusted HR for InSDNN <1 SD from mean 1.45 (95 % CI [1.13–1.85], p=0.003)		
Kikuya et al. 2000 ^{cz}	1,542	Ambulatory blood pressure monitor	SDNN	Patients in lowest tertile have increased risk of all-cause mortality (HR 3.70, p=0.003)		
La Rovere et al. 1998 ^o ATRAMI trial	1,284	24-hour Holter monitor	SDNN	SDNN <70 ms had increased risk of CV-related death (RR 5.3, 95 % CI [2.49–11.4], p<0.0001) compared to >105 ms		
Klieger et al. 1987 ¹⁴	808	24-hour Holter monitor	SDNN	SDNN <50ms had increased risk of all-cause mortality compared with >100 ms (34 % versus 9 %, p <0.0001, RR 5.3)		
Zuanetti et al. 1996 ¹⁶ GISSI-2 trial	567	24-hour Holter monitor	SDNN, rMSSD, NN50+	Risk of all-cause mortality elevated for NN50+ <200, SDNN <70 ms, or rMSSD <17.5 ms (RR 2.8–3.5)		
Adamson et al. 2004 st	288	CRT-P	SDAAM	Elevated risk of all-cause mortality for SDAAM < 50 ms (HR 3.20, p=0.02)		
Sherazi et al. 2015 ¹⁵ MADIT-CRT trial	719	CRT-D	SDNN, SDANN, SDNNIX, rMSSD, VLF, LF, HF, LF/HF	SDNN <93ms associated with increased all-cause mortality (HR 2.10, 95 % CI [1.14–3.87], p=0.017)		
Nolan et al. 1998° 433 UK-Heart trial		24-hour Holter monitor	SDNN, rMSSD, sNN50	SDNN <93ms has all-cause mortality RR 1.62 (95 % CI [1.16–2.44])		

CRED = cardiac resynchronisation therapy definitiator, CREP - cardiac resynchronisation therapy pacemaker, H= high frequency power, HRV = heart rate variability, LF = low frequency power, LFR = heart packer, Members power, LFR = heart packer, LFR = he



GRAND ROUNDS



23

HRV: Not just for the sick

 Daily recordings of HRV are superior at increasing fitness and exercise performance than training based on conventional methods





GRAND ROUNDS




But Why? HR and HRV Hypotheses


- High HR increases hemodynamic stress and shortens diastolic phase
 - · Increased mechanical load, tensile and shear stress
 - Increased BP and cardiac work
 - Increased oxygen consumption
- High HRV is a marker of sympathetic overactivity
 - · Increased VF risk
 - Increased arrhythmia risk
 - · Increased insulin resistance
- Increased activity levels can lead to lower resting HR and higher HRV!





GRAND ROUNDS













The Six Degrees of Freedom

Winneapolis Roundston

GRAND ROUNDS








But How? HR and HRV

- 1. Pulse oximetry
 - 1. Ratio of red to infrared light
- 2. Photoplethysmography (PPG)
 - 1. Optical technique that detects blood volume changes in microvascular bed
 - 2. Basically all devices use this technique
- 3. ECG
 - 1. Apple Watch and AliveCor



GRAND ROUNDS






The Devices

Company	Product name	Biological measurement	All studies on PubMed ^a	Number of clinical trials ^b	Number of cardiovascular clinical trials ^c	FDA status ^d
Watches						
Adidas	miCoach Fit Smart	HR, PA	0	1	1	Not cleared or approved
Apple	Apple Watch	HR, PA, falls, sleep and ECG	135	49	18	Cleared
Biobeat	BB-613WP	HR, PA and cuff-less BP	0	9	3	Cleared
Fitbit	Flex, One, Charge	HR, PA and sleep	612	530	40	Cleared
Garmin	Vivoactive, Vivofit, Forerunner	HR, PA and sleep	51	55	12	Not cleared or approved
Withings	Steel HR, Move, Move ECG, Pulse HR	HR, PA, sleep, ECG and SPO ₂	20	3	2	Not cleared or approved
AliveCor	KardiaMobile	HR, single-lead and 6-lead ECG	28	13	11	Cleared
Oura	Oura Ring	HR, PA and sleep	7	7	0	Not cleared or approved





GRAND ROUNDS






The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation ~420,000 patients over 8 months 2,161 patients (0.52%) received irregular pulse notification · Whether a PPG device could detect AF in those without AF history · 450 participants returned EKG patches Irregularity detected -> • AF present in 34% • 4 more readings taken at rest • PPV of 0.84 for AF on EKG patch with • If irregular -> notification sent irregular pulse notification · Telemedicine visit initiated and EKG patch mailed to wear 7 days Subsequent Deep Neural Network training led to sensitivity of 98% and • Surveys administered 90 days after specificity of 90% in pre-cardioversion initial notification patients **GRAND** ROUNDS























At Oura, we know that you are the source of your truth. Health starts from understanding you. And great health starts with good sleep.








GRAND ROUNDS





45















the Pager Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation: BASEL Wearable Study GET ACCESS Diego Mannhart, Mirko Lischer, Sven Knecht, Jeanne du Fay de Lavallaz, Ivo Strebel, Teodor Serban, David Vögeli, Beat Schaer Stefan Osswald, Christian Mueller, Michael Kühne, Christian Sticherling, and Patrick Badertscher · 201 consecutive patients presenting to cardiology service at a tertiary Sensitivity (95% CI) 85% (72-94%) 85% (72-94%) 58% (42-72%) 66% (51-79%) 79% (64-89%) center Specificity (95% CI) 69% (60-77%) 75% (67-83%) 75% (66-82%) 75% (67-83%) 79% (70-86%) Inconclusive tracings 18% 17% 24% 21% 26% AF present in 32% Preferred Choice*a Limit of HR interpretation*b 50-150 bpm 50-120 bpm No information 50-120 bpm 50-100 bpm · Manual review confirmed 99% of Battery capacity*c 144 h*d 90 h / 2 y*e inconclusive tracings in single lead Price*d 244 265 303 147 **ECG** *a: Out of 165 analyzed patients, 10 patients were not able to decide between the available devices
*b: Information obtained from manufacturers website, 11/21
*c: Time with GPS disabled
*d: Information obtained on digitec.ch on 12.11.21, no discounts / special offers were included in the price, price includes
*tax / all prices in CHF
*e: 90 h net operating time, under regular use up to 2 years GRAND **ROUNDS**












Move More References


- Bayoumy, Karim, et al. "Smart wearable devices in cardiovascular care: where we are and how to move forward." Nature Reviews Cardiology 18.8 (2021): 581-599
- Blond, K., Brinkløv, C. F., Ried-Larsen, M., Crippa, A. & Grøntved, A. Association of high amounts of physical activity with mortality risk: a systematic review and meta-analysis. Br. J. Sports Med. 54, 1195–1201 (2020).
- · Lee, I.-M. et al. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern. Med. 179, 1105 (2019)
- Zhang, D., Wang, W. & Li, F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta-analysis. Can. Med. Assoc. J. 188, E384–E392 (2016)
- Fox, K. et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372, 817–821 (2008)
- Singh N, Moneghetti KJ, Christle JW, Hadley D, Plews D, Froelicher V. Heart Rate Variability: An Old Metric with New Meaning in the Era
 of using mHealth Technologies for Health and Exercise Training Guidance. Part One: Physiology and Methods. Arrhythm Electrophysiol
 Rev. 2018 Aug;7(3):193-198. doi: 10.15420/aer.2018.27.2. PMID: 30416733; PMCID: PMC6141929.
- Singh, N. et al. Heart rate variability: an old metric with new meaning in the era of using mHealth technologies for Health and Exercise Training Guidance. Part Two: Prognosis and Training. Arrhythmia Electrophysiol. Rev. 7, 247–255 (2018).
- Kiviniemi AM, Hautala AJ, Kinnunen H et al. Daily exercise prescription on the basis of HR variability among men and women. Med Sci Sports Exerc. 2010;42:1355–63. doi: 10.1249/MSS.0b013e3181cd5f39.
- Perez, M. V. et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med. 381, 1909–1917 (2019).
- Tison, G. H. et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 3, 409 (2018)



GRAND ROUNDS







Fast Facts





- OSA predicted a 2.4 increase in mortality and a higher CVD incidence over 7.5 years in more than 5,000 participants in the MESA cohort who were free of known CVD at baseline
- Up to 50% of OSA patients may have hypertension, and 30% of hypertensive patients will likely have OSA
- Prevalence of sleep disordered breathing is higher in patients with AF than matched controls; AF harder to control with antiarrhythmics and more likely to recur after ablation



GRAND **ROUNDS**















GRAND ROUNDS



63

sleep number.





- 10 billion hours of sleep data from 1.8 billion sleep sessions
- The 360® smart bed effortlessly adjusts throughout the night
- 28 more minutes of restful sleep per night—170 hours per year
- Collaboration with Mayo Clinic
 - · Sleep Number funding several studies including daytime sleepiness and CV implications
 - · Underserved community research: disordered sleep in Somali population
 - Disrupted sleep and markers of aging (telomeres, senescence)




GRAND ROUNDS









Life's Essential Pod 3 Cover \$2,495 \$2,445 \$50 off Order now. Sale ends soon King \$2,495 \$2,445 **~** Pod 2 Cover Pod 3 Mattress \$3,795 \$3,695 \$100 off King fits onto any mattress. Each side cools and heats you and your partner, all while tracking your sleep without a wearable. Pod 3 Max The Pod Mattress improves your sleep, gives you more energy, and upgrades your entire sleep experience. Each side cools and heats you and your partner all while tracking your sleep without a wearable. \$19/mo \$15/mo* Optimize your sleep with 8+ Pro Included with the Pod **GRAND ROUNDS**




How to get healthy sleep references


- Yeboah J., Redline S., Johnson C., et al. "Association between sleep apnea, snoring, incident cardiovascular events and all-cause mortality in an adult population". MESA. Atherosclerosis. 2011;219:963-968.
- Silverberg D.S., Oksenberg A., Iaina A. "Sleep-related breathing as a of hypertension: fact or fiction?". Curr Opin Nephrol Hypertens 1998;7:4: 353-357.
- Stevenson I.H., Teichtahl H., Cunnington D., Ciavarella S., Gordon I., Kalman J.M. "Prevalence of sleepdisordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function". Eur Heart J 2008;29:1662-1669.
- Monahan K., Brewster J., Wang L., et al. "Relation of the severity of obstructive sleep apnea in response
 to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter". Am J Cardiol 2012;110:369-372.
- Ng C.Y., Liu T., Shehata M., Stevens S., Chugh S.S., Wang X. "Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation". Am J Cardiol 2011;108:47-51.
- Te Lindert BHW, Van Someren EJW. Skin temperature, sleep, and vigilance. Handb Clin Neurol. 2018;156:353-365.
- Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and allcause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart. 2013 Jun;99(12):882-7.




GRAND ROUNDS



















Measuring metabolic fuels: fats or carbs


Physiology range for the overall measured respiratory exchange ratio (RER)


The protein Carbohydrate works and the stock of the core of the core




















Table 11. Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24-Hour ABPM Measurements (Table view)

Clinic	НВРМ	Daytime ABPM	Nighttime ABPM	24-Hour ABPM
120/80	120/80	120/80	100/65	115/75
130/80	130/80	130/80	110/65	125/75
140/90	135/85	135/85	120/70	130/80
160/100	145/90	145/90	140/85	145/90

Meta-analyses of RCTs have identified clinically useful reductions in SBP and DBP and achievement of BP goals at 6 months and 1 year when self-monitoring of BP has been used in conjunction with other interventions, compared with usual care.







GRAND ROUNDS



Life's Essential


85


ABPM

- A systematic review by USPSTF: ABPM provided a better method to predict long-term CVD outcomes than did office BPs
 - · Evidence suggests HBPM is similar
- Every 15-30 min during day and 15-60 min night
- Mean blood pressure, day/night and nocturnal dipping, early morning BP surge, symptomatic hypotension
- Medicare claims for ABPM between 2007 and 2010 were reimbursed at a median of \$52 and were submitted for <1% of beneficiaries
 - · ALWAYS covered!!!
 - · Masked HTN, white coat HTN, response to treatment









Continuous Glucose Monitors

- Real-time CGM or intermittently scanned CGM should be offered for diabetes management in adults on multiple daily injections or insulin pumps
- Clear data for Type 1, murky for Type 2





GRAND ROUNDS



89

Non-diabetics?

- · Higher glucose variability increases:
 - CVD and CVD Death
 - Alzheimer's
 - Frailty
 - Cancer Death
 - · All-cause mortality
- Today's normal patient is tomorrow's diabetic
- · Cost-prohibitive







Life's Essentia








How to manage diabetes

- Raghavan, Sridharan, et al. "Diabetes mellitus—related all-cause and cardiovascular mortality in a national cohort of adults." Journal of the American Heart Association 8.4 (2019): e011295.
- American Diabetes Association; Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin Diabetes 1 January 2022; 40 (1): 10–38.
- Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S120-7.
- Zhang X, Li J, Zheng S, Luo Q, Zhou C, Wang C. Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis. Biosci Rep. 2017 Sep 7;37(5):BSR20170947
- Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004 Oct 12;63(7):1187-92.
- Pérez-Tasigchana RF, León-Muñoz LM, Lopez-Garcia E, Gutierrez-Fisac JL, Laclaustra M, Rodríguez-Artalejo F, Guallar-Castillón P. Metabolic syndrome and insulin resistance are associated with frailty in older adults: a prospective cohort study. Age Ageing. 2017 Sep 1;46(5):807-812.
- Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer. 2017 Jul 1;141(1):102-111.
- Zhang X, Li J, Zheng S, Luo Q, Zhou C, Wang C. Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis. Biosci Rep. 2017 Sep 7;37(5):BSR20170947.



GRAND ROUNDS








The Problem

- 50% of CVD patients consistently take their medications
- Prevalence of the problem is difficult to assess
- This remains an undermanaged problem
- 25% of patients in the Ischemia trial self-reported nonadherence



GRAND ROUNDS
















- 149,576 misses
- 96% adherence rate!
- Medicaid waiver service program • MN, WI, SD, NE, OR, UT, LA, ID
- 4,148 clients
- 6,547 devices









Dose Flip \$60/month

Rental of up to 2 Dose Flips

Health Reminders

Adaptive Equipment

Notifications for caregivers




GRAND ROUNDS



Life's Essential

97





- Identify monitoring methods
- Improve evidence base to better understand adherence
- Develop patient/health provider team-based engagement strategies
- 4 Alleviate health disparities







Medication Adherence

- Ferdinand K, Senatore F, Clayton-Jeter H, et al. Improving Medication Adherence in Cardiometabolic Disease. J Am Coll Cardiol. 2017 Jan, 69 (4) 437–451.
- Kolandaivelu K., Leiden B.B., O'Gara P.T.et al.: "Non-adherence to cardiovascular medications". Eur Heart J 2014; 35: 3267.
- Baroletti S. and Dell'Orfano H.: "Medication adherence in cardiovascular disease". Circulation 2010; 121: 1455.
- Kronish I. and Ye S.: "Adherence to cardiovascular medication: lessons learned and future direction". Prog Cardiovasc Dis 2013; 55: 590.
- Garcia R, Spertus J, Benton M, et al. Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2022 Aug, 80 (8) 755–765. https://doi.org/10.1016/j.jacc.2022.05.045




GRAND ROUNDS




99







Aversion Therapy



- Associate habit with a negative stimulus
- Brain rewired to stop liking the habit



Journal of Substance Abuse Treatment
Volume 5, Issue 1, 1988, Pages 33-36



Life's Essential

Original contribution

Long term outcome of clients treated in a commercial stop smoking program

James W. Smith MD

- 832 patients, 55% male, 3 phases
- 13 month f/u: 52% smoke free, 30% smoking less
- Greatest risk factor to not quit was living with another smoker (70%)



GRAND ROUNDS



Life's Essential

103

35 years later...


- 8 people who smoked 10-20 cigarettes per day
 - · Shock with every puff for 2 weeks
 - · Social support
- 6 stopped completely
- 2 cut down by 50%
- Further studies underway
- Hoping for FDA clearance and further clinical trials











Concerns



- · Device accuracy
 - Inaccurate data more harmful than no data; prevent digital overdiagnosis
 - · Standards by medical societies to evaluate devices
 - · Unified regulatory policies
- Separate actionable data from noise
 - Meaningful use criteria development; data integration
 - RCTs with long term f/u
 - Telehealth curriculum



GRAND ROUNDS



Concerns



- Patient Privacy
 - Data de-identification
 - · HIPAA policy updates
 - · Opt-in arrangements
- Cost
 - Pay close attention to a new health disparity
 - Threefold use difference between high/low SE status
 - \$2,500 up front buy-in for all entry level devices outlined here



GRAND ROUNDS





Devices and Data: Filling the Gap in the Essential 8

Joe Jensen, MD Grand Rounds 23 January 2023



GRAND ROUNDS

